What is the share price of Glenmark Pharmaceuticals Ltd (GLENMARK) today?
The share price of GLENMARK as on 21st April 2025 is ₹1368.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Glenmark Pharmaceuticals Ltd (GLENMARK) share?
The past returns of Glenmark Pharmaceuticals Ltd (GLENMARK) share are- Past 1 week: -2.87%
- Past 1 month: -10.26%
- Past 3 months: -8.72%
- Past 6 months: -20.27%
- Past 1 year: 31.70%
- Past 3 years: 201.76%
- Past 5 years: 333.99%
What are the peers or stocks similar to Glenmark Pharmaceuticals Ltd (GLENMARK)?
The peers or stocks similar to Glenmark Pharmaceuticals Ltd (GLENMARK) include:What is the dividend yield % of Glenmark Pharmaceuticals Ltd (GLENMARK) share?
The current dividend yield of Glenmark Pharmaceuticals Ltd (GLENMARK) is 0.18.What is the market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹38627.65 Cr as of 21st April 2025.What is the 52 week high and low of Glenmark Pharmaceuticals Ltd (GLENMARK) share?
The 52-week high of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹1830.95 and the 52-week low is ₹985.20.What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) stock?
The P/E (price-to-earnings) ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) is -25.72. The P/B (price-to-book) ratio is 4.92.Which sector does Glenmark Pharmaceuticals Ltd (GLENMARK) belong to?
Glenmark Pharmaceuticals Ltd (GLENMARK) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares?
You can directly buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Glenmark Pharmaceuticals Ltd
GLENMARK Share Price
GLENMARK Share Price Chart
GLENMARK Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GLENMARK Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-219.70 | 4.92 | 0.18% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.79 | 6.34 | 0.53% |
GLENMARK Analyst Ratings & Forecast
Detailed Forecast from 11 analysts
Price Upside
Earnings Growth
Rev. Growth
GLENMARK Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Investor Presentation
View olderGLENMARK Similar Stocks (Peers)
Compare with peersGLENMARK Forecasts
Price
Revenue
Earnings
GLENMARK Share Price Forecast
All values in ₹
All values in ₹
GLENMARK Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
GLENMARK Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
GLENMARK
Income
Balance Sheet
Cash Flow
GLENMARK Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 7,581.67 | 9,116.78 | 9,165.82 | 10,240.79 | 10,833.45 | 11,038.69 | 12,471.57 | 12,339.10 | 13,050.42 | 14,028.06 | ||||||||||
Raw Materials | 2,442.74 | 3,073.93 | 2,904.86 | 3,421.01 | 3,570.56 | 3,809.43 | 4,396.42 | 4,498.19 | 4,608.99 | 11,280.56 | ||||||||||
Power & Fuel Cost | 120.47 | 127.02 | 137.48 | 165.26 | 173.69 | 164.67 | 200.64 | 111.75 | 124.00 | |||||||||||
Employee Cost | 1,378.20 | 1,640.81 | 1,871.84 | 2,056.07 | 2,254.78 | 2,343.71 | 2,447.42 | 2,600.78 | 2,868.14 | |||||||||||
Selling & Administrative Expenses | 1,395.79 | 1,589.86 | 1,523.27 | 1,750.21 | 1,667.02 | 1,453.55 | 1,543.27 | 1,752.30 | 1,708.60 | |||||||||||
Operating & Other expenses | 787.32 | 692.04 | 1,021.60 | 887.12 | 1,276.84 | 1,088.19 | 1,657.76 | 1,751.06 | 2,208.99 | |||||||||||
EBITDA | 1,457.15 | 1,993.12 | 1,706.77 | 1,961.12 | 1,890.56 | 2,179.14 | 2,226.06 | 1,625.02 | 1,531.70 | 2,747.50 | ||||||||||
Depreciation/Amortization | 234.28 | 264.37 | 301.88 | 325.91 | 417.17 | 443.55 | 486.72 | 569.17 | 581.91 | 512.15 | ||||||||||
PBIT | 1,222.87 | 1,728.75 | 1,404.89 | 1,635.21 | 1,473.39 | 1,735.59 | 1,739.34 | 1,055.85 | 949.79 | 2,235.35 | ||||||||||
Interest & Other Items | 178.89 | 237.32 | 285.57 | 334.59 | 377.32 | 353.11 | 298.10 | 349.04 | 515.97 | 288.91 | ||||||||||
PBT | 1,043.98 | 1,491.43 | 1,119.32 | 1,300.62 | 1,096.07 | 1,382.48 | 1,441.24 | 706.81 | 433.82 | 1,946.44 | ||||||||||
Taxes & Other Items | 300.94 | 382.67 | 315.46 | 375.63 | 320.11 | 412.44 | 499.54 | 409.56 | 1,935.49 | 2,122.26 | ||||||||||
Net Income | 743.04 | 1,108.76 | 803.86 | 924.99 | 775.96 | 970.04 | 941.70 | 297.25 | -1,501.67 | -175.82 | ||||||||||
EPS | 26.85 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | -6.23 | ||||||||||
DPS | 2.00 | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | ||||||||||
Payout ratio | 0.07 | 0.05 | 0.07 | 0.06 | 0.09 | 0.07 | 0.07 | 0.24 | — | -0.40 |
GLENMARK Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
GLENMARK Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Glenmark Pharmaceuticals Ltd | -25.72 | 4.92 | 0.18% |
Sun Pharmaceutical Industries Ltd | 43.72 | 6.24 | 0.77% |
Cipla Ltd | 29.61 | 4.55 | 0.86% |
Torrent Pharmaceuticals Ltd | 66.50 | 16.07 | 0.86% |
GLENMARK Stock Price Comparison
Compare GLENMARK with any stock or ETFGLENMARK Shareholdings
GLENMARK Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
GLENMARK Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
GLENMARK Shareholding Pattern
GLENMARK Shareholding History
Mutual Funds Invested in GLENMARK
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.5711% | Percentage of the fund’s portfolio invested in the stock 1.86% | Change in the portfolio weight of the stock over the last 3 months 0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/85 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3477% | Percentage of the fund’s portfolio invested in the stock 1.40% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 61/115 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9710% | Percentage of the fund’s portfolio invested in the stock 1.64% | Change in the portfolio weight of the stock over the last 3 months 0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 52/100 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing GLENMARK stock
Looks like this stock is not in any smallcase yet.
GLENMARK Events
GLENMARK Dividend Trend
GLENMARK has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.19%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.86 every year
Dividends
Corp. Actions
Announcements
Legal Orders
GLENMARK Upcoming Dividends
No upcoming dividends are available
GLENMARK Past Dividends
Cash Dividend
Ex DateEx DateSep 13, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 12, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Dividend/Share
₹2.50
Ex DateEx Date
Sep 17, 2020
GLENMARK Stock News & Opinions
Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the paid up equity share capital has increased 28,22,00,809 equity shares of Re. 1 each aggregating to Rs. 28,22,00,809/-. Powered by Capital Market - Live
The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity Amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark's product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets (5 mg to 30 mg), marketed by Teva Women's Health, Inc. Distribution is scheduled to begin in May 2025. According to IQVIA, sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million. Commenting on the launch, Marc Kikuchi, president with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology. The company reported a consolidated net profit of Rs 347.96 crore in Q3 FY25 as compared with net loss of Rs 351.37 crore in Q3 FY24. Net sales increased 34.2% YoY to Rs 3,301.90 crore in Q3 FY25. The counter declined 1.34% to settle at Rs 1,356.95 on Wednesday, 17 April 2025.Powered by Capital Market - Live
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall'2 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025. According to IQVIA sales data for the 12-month period ending February 2025, the Adderall' Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million. Powered by Capital Market - Live
Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1371.95, down 0.32% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 2.16% on the day, quoting at 22882.3. The Sensex is at 75328, up 2.01%.Glenmark Pharmaceuticals Ltd has lost around 3.54% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has increased around 0.27% in last one month and is currently quoting at 19976.3, up 2.51% on the day. The volume in the stock stood at 4.59 lakh shares today, compared to the daily average of 6.56 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 1376.9, up 0.02% on the day. Glenmark Pharmaceuticals Ltd jumped 30.44% in last one year as compared to a 1.61% rally in NIFTY and a 9% spurt in the Nifty Pharma index.The PE of the stock is 16.86 based on TTM earnings ending December 24.Powered by Capital Market - Live
Glenmark Pharmaceuticals has appointed Anurag Mantri as President (Senior Management Personnel) with effect from 07 April 2025. Further, V.S. Mani, Executive Director & Global Chief Financial Officer of the Company has decided to step down with effect from 26 May 2025. The candidature of Anurag Mantri to the office of Executive Director & Global Chief Financial Officer will be put up before Audit Committee, Nomination & Remuneration Committee and Board of the Company in the ensuing committee meetings/Board meeting for approval and once approved, he will then be appointed as Executive Director and Global Chief Financial Officer. Powered by Capital Market - Live
Vancomycin injection is used alone or in combination with other medications to treat certain serious infections, such as endocarditis (infection of the heart lining and valves), peritonitis (inflammation of the lining of the abdomen), and infections of the lungs, skin, blood, and bones. It belongs to a class of medications called glycopeptide antibiotics and works by killing the bacteria that cause infections. Glenmark's Vancomycin Hydrochloride for Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, marketed by Mylan Laboratories. According to IQVIA' sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP market achieved annual sales of approximately $39.3 million. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024. The scrip shed 0.58% to Rs 1,531.05 on the BSE Powered by Capital Market - Live
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories, NDA 209481. According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market2 achieved annual sales of approximately $39.3 million. Powered by Capital Market - Live
The product has been determined to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), developed by Alcon Laboratories, Inc. With this approval, Glenmark Therapeutics Inc., USA, will distribute the product in the US market, further expanding the company's ophthalmic portfolio. Olopatadine ophthalmic (eye) drops are used to treat itching of the eye caused by a condition known as allergic conjunctivitis (pink eye). This medicine is also used to treat eye itching or redness caused by pollen, ragweed, grass, animal hair, or dander. According to Nielsen syndicated data for the 52-week period ending 22 February 2025, the Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), achieved annual sales of approximately $50.7 million. Commenting on the launch, Marc Kikuchi, president & business head of North America, said, 'We are pleased to continue expanding our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.Powered by Capital Market - Live
Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.Powered by Capital Market - Live
The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety. Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, 'Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024. The scrip fell 1.38% to currently trade at Rs 1,381.15 on the BSE.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.97%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 4.66% to 3.42%